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Abstract  A cross-sectional study screened lymphedema, 
impaired upper limb function (ULF) and quality of life (QOL) 
in women post-breast cancer. Women attending review 
appointments who had completed surgery, chemotherapy 
and radiotherapy, were without recurrence, and could 
complete questionnaires in English were invited. Medical 
records were reviewed and questionnaires completed: the 
Morbidity Screening Tool (MST), Disability of the Arm, 
Shoulder and Hand questionnaire (DASH), and Functional 
Assessment of Cancer Therapy for breast cancer QOL 
questionnaire (FACTB+4). The vertical perometer (400T) 
measured percentage upper limb volume difference (%LVD), 
with 10% or greater difference diagnosed as lymphedema. 
Of 617 participants (mean age 62.3y, SD 10.0; mean time 
since treatment 63.0 months, SD 46.6), sufficient 
questionnaire data were available for 613 and perometry data 
for 417. Using the MST, 21.9% self-reported impaired ULF, 
19.8% lymphedema, and 9.2% both. Based on %LVD,  
26.5% had lymphedema. Histogram analysis for individuals 
in the first eight twelve-month intervals after treatment found 
impaired ULF prevalence peaked at three to five years and 
lymphedema at three years. Significantly worse function 
(DASH) and QOL (FACT B+4) resulted for those with 
morbidity (p<0.000). This provides evidence that impaired 
ULF and lymphedema negatively affect QOL years after 
treatment and are not necessarily linked. 
Keywords Lymphedema; Upper Limb Function; 
Prevalence; Quality of Life; Impacts 
 
1. Introduction 
Increasing survival rates after breast cancer have led to 
greater focus on improving functional outcomes, reducing 
morbidity and improving quality of life. The necessary 
rigour of treatment can lead to long term morbidity, 
including impaired upper limb range of motion, strength and 
function, and swelling (lymphedema) that may develop 
immediately, or may emerge years later [1]. 
Lymphedema is an accumulation of interstitial fluid in the 
tissues due to interruption in the lymphatic system and can 
lead to skin fibrosis and cellulitis, as well as psychological 
sequelae. Prevalence estimates vary widely, from 2 to 86%, 
due to differences in study samples, measurement techniques, 
and diagnostic criteria [2]. Growing consensus indicates 
greater risk of lymphedema after axillary lymph node 
dissection (ALND), and radiotherapy to the axilla [3]. 
Previously, people have been recommended to avoid activity 
in the affected limb, with a link expected between treatment 
in the dominant limb and lymphedema, although this is 
unclear and requires further investigation [4].Several studies 
have compared breast cancer survivors with and without 
lymphedema, finding greater psychological morbidity and 
poorer function and quality of life in the former [5].  
Reduced mobility of the shoulder, reduced grip strength, 
and pain can also develop, affecting work and activities of 
daily living [3,6]. A systematic review looking at prevalence 
of upper limb morbidity found wide variation, but concluded 
that impaired upper limb function is a long-term problem 
after breast cancer treatment, affecting quality of life [7]. 
However, several authors highlight the lack of understanding 
of relationships between late morbidity and activities of daily 
living, occupation, and quality of life [3,6,8]. 
Thomas-MacLean and colleagues advocate for research into 
inter-relationships between forms of arm morbidity, such as 
lymphedema and impaired upper limb function [8].  
Lymphedema measurement often focuses on limb volume, 
using volumetry (water displacement), or calculations from 
circumferential measurement of segments of the limb. 
Perometry (opto-electronic scanning) and multifrequency 
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bioelectrical impedance [1,9,10]. Lymphedema is frequently 
diagnosed through comparison of the affected and unaffected 
limbs, or within the same limb over time, most commonly 
specified as differences equal to or greater than 10%, 2cm, 
5cm or 200ml in limb circumference or volume (as 
appropriate) [11]. A comparison study suggests that an 
increase in percentage limb volume of 10% or more is the 
most conservative classification, allowing for pre-existing 
bilateral limb volume differences [11]. Some evidence 
suggests that patient self-report provides an earlier and more 
sensitive diagnosis that does not rely on pre-operative limb 
volume measurements or expensive instrumentation and 
explores functional and psychosocial dimensions [1,4,11]. A 
combined approach is advocated by some [1]. Upper limb 
morbidity has been evaluated in various ways, including 
goniometry measurement of shoulder range of motion, 
dynamometry for grip strength, and self-report of pain and 
ability to perform activities of daily living [3]. 
Evidence suggests that when detected early, therapeutic 
intervention can lead to greater success in managing upper 
limb morbidity, with improved outcomes and quality of life 
[12], raising the importance of further investigation. A study 
was designed that screened for lymphedema and impaired 
arm function after breast cancer treatment, enabling 
investigation of the following research questions:  
1. What are the prevalence rates of impaired upper limb 
function (ULF) and lymphedema in a cross-sectional sample 
of women who have completed treatment for breast cancer, 
and what is the relationship between the two? 
2. How do the prevalence rates of impaired ULF and 
lymphedema differ between women who are at different 
time-points post-treatment in the sample? 
3. To what extent do impaired ULF and lymphedema 
impact on quality of life, function and occupation of those 
within the sample, and do their impacts differ? 
4. Does dominance of the treated limb affect prevalence of 
impaired ULF and lymphedema, and their impacts of 
morbidityon quality of life and function? 
A further research question, relating to relationships 
between morbidity and treatment characteristics, will be 
dealt with elsewhere. 
2. Material and Methods 
2.1. Study Design 
A cross-sectional study screened for impaired ULF and 
lymphedema in women who had completed treatment for 
breast cancer (surgery, chemotherapy and radiotherapy), 
between November 2009 and May 2010. The South East 
Scotland Research Ethics Committee classified this as 
service review and full ethical review was conducted within 
the Higher Education Institution. 
2.2. Procedure and Measurement 
Women awaiting review appointments at the Breast Clinic, 
who did not have recurrence, and who could complete 
questionnaires in English were provided with information 
and a consent form. If willing, they completed a 
questionnaire booklet, and participated in objective tests in a 
private clinic room, and medical records were reviewed. 
The vertical perometer (400T) was used to objectively 
diagnose lymphedema where LVD was 10% or greater [11]. 
Evidence of validity and reliability exists in in women 
post-breast cancer, and with lymphedema [13,14]. A 
previously developed protocol was used to standardise the 
limb proportion being measured, position within the 
measurement frame, and rest period prior to testing Bulley et 
al., in press, European Journal of Physiotherapy  
Questionnaires included the DASH questionnaire [15]; the 
Functional Assessment of Cancer Therapy (FACTG) quality 
of life questionnaire with breast cancer sub-scale (FACTB) 
and additional questions relating to the upper limb 
(FACTB+4) [16]; anda Morbidity Screening Tool (MST) 
developed by the research group. The DASH Questionnaire 
focuses on day-to-day function of the upper limb and 
numerous studies support its psychometric properties in 
varied populations and translations [17].Previous research 
supports the reliability, validity and practicality of the FACT 
B and FACT B+4 [18]. The MST requests participant 
characteristics such as handedness and changes in 
occupation and then focuses on impaired ULFand 
lymphedema. It first establishes whether or not the person 
perceives that there is a problem, and then explores its 
impacts on activities and participation, as recommended by 
the World Health Organization [19]. Its validity was studied 
by investigating relationships with established objective 
(n=434) and subjective measures (n=613) Bulley et al., in 
press, Biomed Research International. These included 
Perometry limb volume measurement [9], upper limb 
combined range of motion (ROM) [20], the DASH and 
FACT B+4 questionnaires. Results supported use of the 
MST; for example, self-reported ULF impairment 
differentiated significantly as expected in relation to 
‘hand-behind-back’ range of motion (Mann Whitney 
U=11784.5; p=0.001), DASH scores(u=7145.5; p<0.001), 
and FACT G scores(u=13891.5; p<0.001). Self-reported 
lymphedema differentiated significantly as expected in 
relation to perometry percentage limb volume differences 
(%LVD) in those with unilateral treatment (U=112128; 
p<0.001), FACT G scores (u=14617.0; p<0.001), and the 
FACT B+4 arm-specific subscale (u=9671.5; p<0.001). 
2.3. Analysis 
Non-normal distributions (Shapiro-Wilk test: 
p=0.000-0.004) led to selection of non-parametric analysis 
(significance set at p<0.05), using  the Mann-Whitney U 
test (two groups) and Kruskal Wallis H test (multiple groups) 
for between-group differences; post-hoc analysis used the 
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Relationships were explored with the chi-square test for 
categorical variables. 
3. Results 
Of 617 women who participated (approximately 46.6% 
recruitment rate) 613 had sufficient subjective data for 
analysis and 417 had subjective and objective data. A 
different response rate results for each analysis, due to 
variable questionnaire completion.  
Overall, participants were a mean age of 62.3 (complete 
data: n=595; SD 10.0; range 31-90 years) and completed 
treatment (surgery and any chemotherapy or radiotherapy) 
63.0 months (mean) previously (n=593; SD 46.6, range 
0-360 months). Of 596 with data, 7% (n=44) had bilateral 
breast cancer; of those with unilateral treatment, 25.5% 
received mastectomy and 73.6% wide local excision (WLE). 
Of 91.1% with unilateral axillary surgery 35.0% had full 
clearance, while 56.2% received either 4-node axillary 
sampling or sentinel lymph node biopsy (SLNB). Of 596 
with data, 82.2% received breast radiotherapy, and 24.0% 
axillary. Out of 512, 40.2% received chemotherapy, and 75.2% 
received, or were still receiving, hormone therapy. 
3.1 Prevalence of Impaired ULF, Lymphedema and Both  
As summarised in Table 1, approximately one fifth of 
participants self-reported impaired ULF, and one fifth 
lymphedema.  Using perometry, 26.5% of 434 participants 
with unilateral treatment had lymphedema. Almost a tenth 
reported co-existence of impaired ULF and lymphedema. 
Table 1 provides participant characteristics for each of these 
categories and summarises inferential analysis: no 
significant differences in age were found between those 
self-reporting impaired upper limb function or not, 
lymphedema or not, and for those with both types of 
morbidity or not. 
3.2. Differences in Morbidity Prevalence with Time since 
Treatment 
Table 1 summarises descriptive and inferential analysis 
comparing months since treatment according to morbidity 
category; no statistically significant differences were found 
for participants with self-reported impaired upper limb 
function and those without, for those with lymphedema and 
those without and for those with both types of morbidity and 
those with either type or neither.Histogram analysis explored 
differences in prevalence of morbidity in participants who 
were in the first to eighth 12-month time interval categories 
post-treatment, where n>30 for each. For impaired ULF, 
from a median of 63.5 participants in each category, over the 
categories 21.6% impairment was reported (median no 
impairment = 49.5; impairment = 10.5). For lymphedema, 
there were 64.5 participants per category (median), with  
22.8% impairment reported over the categories (median: no 
impairment = 51.5; impairment = 12.0). Figures 1 and 2 
illustrate the differences in percentage impairment reported 
over each of the eight years; prevalence of impaired ULF in 
the sample peaked in the groups who were three to five years 
post-treatment, while prevalence of lymphedema was 
greatest year three, and then remained fairly static. 
3.3. Impacts of Morbidity 
Comparison of DASH and FACT B subscale scores was 
undertaken for those responding they had impaired ULF, 
lymphedema, both, and neither (n=473), summarised in 
Table 2. The Kruskal Wallis H test found significant 
differences between the four groups. Post hoc analysis 
(Mann-Whitney U test; Bonferroni correction requiring 
p<0.008) found significant differences (p<0.007) in all 
groups for all variables, with the exceptions of comparisons 
between those with only impaired ULF and those with only 
lymphedema (DASH: U=1298.4, p=0.117; FACTB: 
U=1499.0, p=0.690; Breast cancer subscale: U=1205.0, 
p=0.035; Arm subscale: U=1248.5, p=0.061), and between 
those with neither type of morbidity and those with impaired 
ULF: for the Breast cancer subscale score only (U=7156.5, 
p=0.009). 
Lastly, relationships between morbidity and occupational 
status categories were explored (Table 3). Chi2 results were 
statistically significant for both impaired ULF and 
lymphedema, supporting the negative impacts of morbidity. 
Descriptively, 14.4% of people with impaired ULF and 
15.5% with lymphedema self-reported that they had stopped 
working since their breast cancer treatment, compared with 
5.8% and 6.1% of those without impairment. Upper limb 
morbidity appears to be associated with negative changes in 
occupational status. 
3.4. Relationships between Morbidity and Dominance of 
the Limb Treated 
Table 4 demonstrates that for those with self-reported 
impaired ULF and lymphedema, proportions of people 
treated on their dominant and non-dominant sides are 
approximately equal, with no significant difference in the 
impacts of treatment according to DASH and FACT B (and 
subscale) scores. The only borderline statistically significant 
result was that higher quality of life scores relating to breast 
cancer symptoms were found in those with impaired ULF 
who were not treated in their dominant limb. 
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Figure 1.  Percentage prevalence of impaired upper limb function during the first eight years post-treatment 
 
 
 
Figure 2.  Percentage prevalence of lymphedema during the first eight years post-treatment 
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Table 1.  Perceived morbidity prevalence according to the Morbidity Screening Tool and participant characteristics 
 Perceived impaired upper limb function Perceived  
lymphedema 
Both impaired upper limb function and 
lymphedema 
Yes No Yes No Yes No 
Perceived morbidity - n (%1): 
(response=5802; 5953; 5754) 
127  
(21.9%) 
453 
(78.1%) 
118 
(19.8%) 
477 
(80.2%) 
53 
(9.2%) 
522 
(90.8%) 
Age (years): median (range) 
(response=5802; 5953; 5754) 
62.00 
(38.00-85.00) 
61.00 
(31.00-90.00) 
61.00 
(41.00-87.00) 
62.00 
(31.00-90.00) 
61.00 
(42.00-82.00) 
62.00 
(31.00-90.00) 
Mann-Whitney U Test U=28093, Z=-0.401, p=.69 U=26168.5, Z=-1.18, p=.24 U=13516.5, Z=-0.28, p=.78 
Monthssince treatment: median (range) 
(response=5751; 5902; 5703) 
51.00 
(5.00-240.00) 
55.00 
(0.00-360.00) 
57.00 
(4.00-360.00) 
53.00 
(0.00-317.00) 
51.00 
(5.00-144.00) 
55.00 
(0.00-360.00) 
Mann-Whitney U Test U=27949, Z=-0.21, p=.84 U=27768, Z=-0.48, p=.96 U=13022.5, Z=-0.59, p =.55 
Unilateral  cancer - n (%1):  
(response=5582; 5713; 5554) 
111  
(91.74) 
406  
(92.91) 
104  
(91.23) 
424 
(92.78) 
49 
(92.45) 
465 
(92.63) 
Mastectomy - n (%1):  
(response=5552; 5693; 5504) 
39  
(32.23) 
114  
(26.27) 
42 
(36.21) 
118 
(26.05) 
21 
(40.38) 
132 
(26.51%) 
Wide Local Excision - n (%1): 
(response=5572; 5713; 5524) 
83 
(68.60) 
326 
(74.77) 
75 
(64.66) 
341 
(74.95) 
31 
(59.62) 
373 
(74.60) 
Axillary full node clearance - n (%1): 
(response=5562; 5703; 5514) 
49 
(40.50) 
149 
(34.25) 
70 
(59.83) 
137 
(30.24) 
29 
(55.77) 
169 
(33.87) 
Axillary sampling / SLNB5 - n (%1): 
(response=5562; 5703; 5514) 
66 
(54.55) 
259 
(59.54) 
47 
(40.17) 
282 
(62.25) 
23 
(44.23) 
298 
(59.72) 
Radiotherapy to the breast - n (%1): 
(response=5612; 5763; 5564) 
100 
(81.97) 
364 
(82.92) 
95 
(80.51) 
380 
(82.97) 
41 
(77.36) 
418 
(83.10) 
Radiotherapy to the axilla - n (%1): 
(response=5602; 5753; 5554) 
35 
(28.69) 
104 
(23.74) 
37 
(31.36) 
104 
(22.76) 
15 
(28.30) 
122 
(24.30) 
Chemotherapy - n (%1): 
 (response=4862; 4963; 4864) 
44 
(42.31) 
151 
(39.53) 
53 
(53.54) 
147 
(37.03) 
17 
(41.46) 
177 
(39.78) 
1. % of respondents with relevant treatment who do / do not self-report morbidity 
2. Perceived impaired upper limb function: response rate for item 
3. Perceived lymphedema: response rate for item 
4. Perceived impaired upper limb function and lymphedema: response rate for item 
5. Four-node axillary sampling or sentinel lymph node biopsy  
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Table 2.  Comparison of DASH and FACT B scores for those with impaired upper limb function, with lymphedema, with both, and with neither: descriptive and inferential analysis 
People who perceive themselves (MST1) to 
have: 
Neither impaired upper 
limb function / 
lymphoedema 
Impaired upper limb 
function only 
Lymphoedema only Both impaired upper limb 
function and 
lymphoedema 
N (%) 321 (67.9) 57 (12.1) 55 (11.6) 40 (8.5) 
Median (range) DASH2 score 2.6 
(0.0-52.6) 
12.5 
(0.0-78.4) 
8.3 
(0.0-67.5) 
25.0 
(2.5-77.6) 
Kruskal Wallis H Test Chi2 =125.0; p=0.000 
Median (range) FACTB3 score 125.0 
(55.3-144.0) 
115.0 
(51.6-143.0) 
118.0 
(64.6-139.0) 
97.4 
(51.8-132.0) 
Kruskal Wallis H Test Chi2 =59.0; p=0.000 
Median (range)  breast cancer subscale score 29.0 
(12.0-36.0) 
27.0 
(9.5-36.0) 
25.0 
(9.0-33.0) 
22.0 
(3.0-33.1) 
Kruskal Wallis H Test Chi2 =65.7; p=0.000 
Median (range) arm subscale score 20.0  
(6.0-20.0) 
17.0 
(6.0-20.0) 
16.0 
(2.0-20.0) 
13.1 
(0.0-20.0) 
Kruskal Wallis H Test Chi2 =156.5; p=0.000 
1. MST: Morbidity Screening Tool;  
2. DASH: Disability of the Arm, Shoulder and Hand questionnaire;  
3. FACT-B: Functional Assessment of Cancer Therapy – Breast Cancer specific quality of life questionnaire. 
Table 3.  Cross-tabulation of upper limb impairment and lymphedema with occupational status since breast cancer treatment (frequency) 
Self-report (MST1) 
Upper limb impairment Lymphedema 
No Yes No Yes 
Employment ceased: n (%) 24 (57.1) 18 (42.9) 26 (60.5) 17 (39.5) 
Reduced hours of employment: n (%) 23 (85.2) 4 (14.8) 20 (74.1) 7 (25.9) 
No change in hours of employment: n (%) 199 (82.6) 42 (17.4) 198 (82.5) 42 (17.5) 
Increased hours of employment: n (%) 2 (50.0) 2 (50.0) 3 (75.0) 1 (25.0) 
Not applicable2: n (%) 165 (73.7) 59 (26.3) 181 (80.8) 43 (19.2) 
Total: n 413 125 428 110 
Chi2with 4 degrees of freedom 17.514, p=0.002 11.678, p=0.020 
1. MST: Morbidity Screening Tool;  
2. Not applicable, for example, retired from employment before treatment for breast cancer
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Table 4.  Analysis of the differences in DASH and FACT B subscale scores according to treatment in the dominant or non-dominant limb for those with 
self-reported impaired upper limb function and lymphedema 
 Those with impaired ULF (MST1): treated in the dominant limb (n=97) 
Those with lymphedema (MST1): treated in the 
dominant limb (n=94) 
 Yes No Yes No 
N (%) 48 (49.5) 49 (50.5) 47 (50) 47 (50) 
Median (range) DASH2 score 
18.1 
(0.0-77.5) 
17.5 
(0.0-78.4) 
15.8 
(0.0-69.8) 
15.2 
(0.0-77.6) 
Mann-Whitney U Test U=1163.5; p=0.928 U=1059.0; p=0.731 
Median (range) FACT-B3 
subscale score 
104.5 
(53.5-143.0) 
112.0 
(51.6-140.0) 
113.8 
(67.5-133.0) 
104.0 
(51.8-139.0) 
Mann-Whitney U Test U=949.0; p=0.102 U=1068.0; p=0.783 
Median (range)  breast cancer 
subscale score 
22.5 
(6.0-36.0) 
26.0 
(3.0-36.0) 
23.9 
(6.0-33.0) 
24.0 
(3.0-33.1) 
Mann-Whitney U Test U=904.5; p=0.050 U=1055.0; p=0.708 
Median (range) arm subscale 
score 
16.0 
(0.0-20.0) 
16.0 
(0.0-20.0) 
16.0 
(0.0-20.0) 
15.0 
(0.0-20.0) 
Mann-Whitney U Test U=1157.0; p=0.890 U=1025.5; p=0.549 
1. MST: Morbidity Screening Tool;  
2. DASH: Disability of the Arm, Shoulder and Hand questionnaire;  
3. FACT-B: Functional Assessment of Cancer Therapy – Breast Cancer specific quality of life questionnaire.  
4. Discussion 
Some interesting insights into upper limb morbidity have 
been found and are discussed in turn. When comparing 
participant characteristics with one UK and one US study 
published in the previous six years [21,22], variations are not 
substantial considering such a heterogeneous population.  
4.1. Prevalence of Impaired Upper Limb Function and 
Lymphedema and Relationships with Dominance of 
the Limb Treated 
The current study found similar proportions of about one 
fifth of participants self-reportingimpaired ULF and 
lymphedema, but under a tenth self-reported both, 
suggesting that they are not frequently linked. Fewer studies 
have looked at the prevalence of impaired ULF than 
lymphedema, but one recent systematic review included 32 
longitudinal or cross-sectional studies and found decreased 
shoulder ROM varied from 1% to 67% prevalence (7 
studies), and arm weakness, 9 to 28% (3 studies) [7]. 
Incidence rates were lowest when estimated by clinicians 
rather than from objective measurement or participant 
self-report; the latter was used by the current study, possibly 
explaining the prevalence estimate being at the mid-to-high 
end of the estimate range [7].  
The current study’s prevalence estimate for lymphedema 
is again at the higher end of the range found in the previously 
mentioned systematic review, 0-34% [7]. In the ALMANAC 
trial, at eighteen months from baseline, 8.4% of ALND 
patients and 3.8% with SLNB self-reported swollen or tender 
arms using the FACT B+4 arm subscale [21].  A recent 
study of incidence and course of lymphedema 
(circumferential measurement) six-to-twelve months 
post-surgery in 347 women found incidence rates of 9-16% 
depending on the criterion used, averaging 12%8. Current 
findings are higher than both studies, possibly reflecting the 
high upper range of time since treatment, as evidence 
suggests incidence or prevalence estimates increase with 
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longer follow-up [3]. The previously mentioned study [8] 
also investigated shoulder abduction and external rotation 
(10% difference indicated deficit); impairments were found 
in 41% and 28% respectively. Although both are greater than 
prevalence of impaired ULF in the current study a very 
similar result of under 10% of participants reporting both 
lymphedema and impaired ULF was found, supporting the 
finding that they are not related in the majority of 
participants.  
The current study found perometry measurement 
estimated lymphedema prevalence 7% higher than 
self-report; lower estimates from self-report were also found 
in a study of 211 women 2.5 years post-treatment: 41% 
compared with 45% (perometry: 10% change pre-to-post 
treatment) [22]. An earlier study of 176 women found the 
opposite, 27.8% from self-report and 11.9%, 0.6% and  
11.4% found by objective criteria (summed arm 
circumferences: difference >5cm or >10%; multifrequency 
bioimpedance: 3+SD above reference score) [23]. Therefore, 
the relationship between subjective and objective prevalence 
estimation is unclear.  
The large number of participants in the current study 
enabled comparisons of prevalence in women at different 
time-points post-treatment, finding that impaired ULF was 
highest at three to five years post-treatment, while 
lymphedema peaked at 28% at three years. Prospective 
studies of lymphedema incidence have found similar results, 
for example, incidence increased from 20% at six months, to 
32% with persistent swelling at three years (n=622) [24]. 
Although investigated less in relation to ULF, one study of 
impaired arm movement found some reduction over four 
years from 37 to 26% prevalence [25]. The persistence of 
arm problems over time in some women supports the current 
study findings. 
The current study found no evidence that prevalence and 
impacts of morbidity are greater when treated in the 
dominant limb. Evidence increasingly suggests that greater 
use of the dominant treated limb is beneficial; one study 
found 80% greater risk of lymphedema with treatment in the 
non-dominant limb [23]. 
4.2. Impacts of Impaired Upper Limb Function and 
Lymphedema 
The current study found that for those self-reporting 
impaired ULF, and those with lymphedema, significantly 
poorer function and quality of life resulted, and co-existence 
of both provided significantly worse scores than either. A 
review of the literature on health-related quality of life found 
poorer psychological well-being in those with lymphedema 
than the general population. Qualitative literature highlights 
contributions from fear, frustration, and poor body image [5] 
and significantly worse FACT B scores have been found in 
women with lymphedema than matched controls [24]. A 
change of at least five points in the FACT B has been stated 
to be clinically relevant [21]. Score differences in the current 
study were well above this threshold: between those with no 
impairment and those with impaired ULF (10 points), 
lymphedema (7 points), and both (28 points). 
The current study also provided evidence that UL 
morbidity can be associated with negative occupational 
changes. One recent study found between 11-44% of 3253 
women, depending on treatment group, gave up activities 
after breast cancer treatment, and over a third of those 
working felt that this had been affected [2]. 
These data further support the increasing trend towards 
avoiding over-treatment of the axilla [3]. Although it is 
positive to note the increasing consensus regarding reduced 
risk of arm morbidity following SLNB, risk of morbidity 
remains, as the long-term effects are not yet known and a 
proportion of women will still require more extensive 
axillary surgery. There is evidence that earlier detection and 
management are most likely to be successful [12]. Therefore 
timely screening for morbidity should be part of follow-up 
care [8] and management of upper limb morbidity is 
important to improve function and quality of life after breast 
cancer treatment.  
4.3. Study Considerations 
The current study is cross-sectional, and some women 
may have returned to clinic review sessions after longer 
periods post-treatment due to upper limb morbidity, rather 
than other concerns. Treatment protocols are likely to have 
developed over the time period, which could have increased 
morbidity prevalence in those with a longer time since 
treatment. However, the lack of significant differences in 
time since treatment among those who did or did not 
self-report impairment does not support these suggestions. 
5. Conclusion 
To conclude, the current study findings found 
approximately a fifth of the study sample to have 
lymphedema, a fifth to have impaired upper limb function, 
and only 9% to have symptoms of both. Prevalence of 
impaired ULF appeared to be greatest among women who 
were three to five years post treatment, and prevalence of 
lymphedema peaked at three years, suggesting that upper 
limb morbidity is an ongoing problem after treatment for 
breast cancer. Statistically significant reductions in daily 
function and quality of life were evident in those with 
morbidity supported by negative impacts on occupational 
status. These insights into prevalence and impacts of upper 
limb morbidity expand our current understanding of the 
relationships between lymphedema and other forms of upper 
limb function, and their differential impacts on activities, 
participation in occupational roles and general quality of life, 
as well as providing further support for the chronicity of 
morbidity. The results support the need for timely screening 
as part of follow-up care and early management to improve 
function and quality of life after breast cancer treatment. 
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Ongoing prospective investigation of these issues will be 
important as treatment protocols for breast cancer continue 
to develop, and further development and evaluation of 
screening and management strategies will be valuable. 
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